Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FimH is a 30 kDa lectin-like adhesin located at the distal tip of type 1 fimbriae in uropathogenic Escherichia coli (UPEC) (UniProt P08191). It is the primary mediator of bacterial attachment to the bladder epithelium (urothelium) by specifically recognizing and binding to terminal mannose residues on glycoproteins like uroplakin Ia. This adhesion is a prerequisite for colonization, biofilm formation, and subsequent invasion of the host cells, which leads to the development of urinary tract infections (UTIs). The binding mechanism involves a catch-bond behavior, where tensile force increases the affinity of FimH for its ligand, helping the bacteria withstand the flow of urine. Because FimH-mediated binding is crucial for pathogenesis, it has become a major target for anti-adhesion therapies. Small-molecule FimH antagonists, such as mannosides like GSK3882347 and Sibofimloc (EB8018), are designed to competitively occupy the mannose-binding pocket of FimH. These drugs effectively prevent bacterial attachment, allowing the pathogen to be cleared naturally by urine flow without the use of traditional bactericidal antibiotics. This approach is particularly promising for treating recurrent UTIs and reducing the selection pressure for antibiotic resistance.
Competitive inhibition of the FimH lectin domain, preventing its binding to mannosylated uroplakin receptors on the host urothelium.
3 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FimH adhesin (FimH).